Valeant Pharmaceuticals International Company Profile (NYSE:VRX)

About Valeant Pharmaceuticals International (NYSE:VRX)

Valeant Pharmaceuticals International logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NYSE:VRX
  • CUSIP: N/A
  • Web: www.valeant.com
Capitalization:
  • Market Cap: $6.10227 billion
  • Outstanding Shares: 347,906,000
Average Prices:
  • 50 Day Moving Avg: $15.38
  • 200 Day Moving Avg: $13.27
  • 52 Week Range: $8.31 - $32.74
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 4.64
  • P/E Growth: -0.63
Sales & Book Value:
  • Annual Revenue: $9.41 billion
  • Price / Sales: 0.65
  • Book Value: $11.19 per share
  • Price / Book: 1.58
Profitability:
  • EBIDTA: $3.9 billion
  • Net Margins: -14.96%
  • Return on Equity: 58.02%
  • Return on Assets: 5.48%
Debt:
  • Debt-to-Equity Ratio: 7.06%
  • Current Ratio: 1.26%
  • Quick Ratio: 0.99%
Misc:
  • Average Volume: 23.24 million shs.
  • Beta: -0.35
  • Short Ratio: 1.44
 
Frequently Asked Questions for Valeant Pharmaceuticals International (NYSE:VRX)

What is Valeant Pharmaceuticals International's stock symbol?

Valeant Pharmaceuticals International trades on the New York Stock Exchange (NYSE) under the ticker symbol "VRX."

How were Valeant Pharmaceuticals International's earnings last quarter?

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) announced its earnings results on Tuesday, May, 9th. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $1.93. The company had revenue of $2.11 billion for the quarter, compared to the consensus estimate of $2.17 billion. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. The company's revenue was down 11.1% on a year-over-year basis. During the same period in the previous year, the business earned ($1.08) EPS. View Valeant Pharmaceuticals International's Earnings History.

Where is Valeant Pharmaceuticals International's stock going? Where will Valeant Pharmaceuticals International's stock price be in 2017?

19 brokerages have issued 1 year price objectives for Valeant Pharmaceuticals International's shares. Their forecasts range from $8.00 to $35.00. On average, they expect Valeant Pharmaceuticals International's share price to reach $16.89 in the next year. View Analyst Ratings for Valeant Pharmaceuticals International.

What are analysts saying about Valeant Pharmaceuticals International stock?

Here are some recent quotes from research analysts about Valeant Pharmaceuticals International stock:

  • 1. According to Zacks Investment Research, "Once an acquisition giant, Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services. After a tumultuous period, Valeant started a rebuilding process with its new CEO, Joseph C. Papa. Even though it is still early to comment on the rebuilding process, but the company’s efforts to sell non-core assets and pay down huge levels of debt is commendable and should bode well in the upcoming quarters. The company reduced its debt by $4.3 billion since the first quarter of 2016.The dermatology business saw some positive trends as the average selling price stabilized. The GI business continues to struggle with weak sales of Xifaxan but should see gain in market share with an increased sales force. Shares have underperformed the broader industry." (7/13/2017)
  • 2. Cantor Fitzgerald analysts commented, "On 5/2/17 Valeant held its annual shareholder meeting. Interestingly, the company’s Say on Pay" vote on executive compensation passed with a ~65% majority, despite both ISS and Glass Lewis voting against the plan. We think this reflects the fact that Valeant’s shareholders support the new CEO and CFO. We also believe that the Board has been re-invigorated with the addition of John Paulson. This was announced 6/19/17." (6/28/2017)
  • 3. Royal Bank Of Canada analysts commented, "We have revised our outlook due to the recent VRX financing and accounting treatment for Siliq revenues. While our revenue forecasts have increased due to Siliq, Adj. EBITDA forecasts have declined slightly. Following a modest increase in net debt, our price target declines to $18." (3/23/2017)
  • 4. Deutsche Bank AG analysts commented, "Lowered EPS on higher op ex, interest expense We updated our model following the company's 4Q results and 10-K filing, our meetings with management last week, and to reflect preliminary assumptions for the planned debt refinancing. Overall, we lowered our EPS estimates based primarily on higher spending and interest expense assumptions (see below), which reduced our DCF-derived PT to $19 (from $20). While our target implies material upside from the current stock price, we are sticking with our Hold rating pending greater visibility on improved demand trends for Xifaxan and other core assets, stabilization of the Dermatology business, and further steps to address the debt load and strengthen the balance sheet. We are encouraged that the company has begun to deliver on the expectations that it has set (as of 4Q), a theme we hope to see continue in the quarters ahead." (3/7/2017)
  • 5. Mizuho analysts commented, "The company is using its recently closed sale of assets to L'Oreal to repay $1.1B of a ~2.8% Term A loan due in 2018 (already excluded from our interest rate calculations). The company plans to refinance its existing credit agreement, issue new Term B loans that extend the maturity of current Term B loans due before 2022 (~$4.3B), issue new secured debt, and repay its remaining Term A loan due in April 2020 ($658M). Valeant also plans to repay a portion of its 6.75% secured debt due in 2018 (current balance is $1.59B). In tandem with this exercise, Valeant plans to relax its maintenance covenants in the revolver (currently $875M) and remove the covenants from its Term B loans. While the refinancing is not surprising, it reflects the cloudy outlook on future earnings, in our view." (3/6/2017)

Are investors shorting Valeant Pharmaceuticals International?

Valeant Pharmaceuticals International saw a decrease in short interest in June. As of June 30th, there was short interest totalling 34,135,143 shares, a decrease of 23.9% from the June 15th total of 44,857,712 shares. Based on an average trading volume of 33,585,673 shares, the short-interest ratio is presently 1.0 days. Currently, 10.1% of the shares of the stock are short sold.

Who are some of Valeant Pharmaceuticals International's key competitors?

Who are Valeant Pharmaceuticals International's key executives?

Valeant Pharmaceuticals International's management team includes the folowing people:

  • Joseph C. Papa, Chairman of the Board, Chief Executive Officer
  • Paul S. Herendeen, Chief Financial Officer, Executive Vice President
  • Christina Ackermann, Executive Vice President, General Counsel
  • Thomas J. Appio, Executive Vice President, Company Group Chairman, International
  • William D. Humphries, Executive Vice President, Company Group Chairman, Dermatology
  • Thomas W. Ross Sr, Lead Independent Director
  • Richard U. DeSchutter, Independent Director
  • Fredric N. Eshelman, Independent Director
  • D. Robert Hale, Independent Director
  • Argeris N. Karabelas Ph.D., Independent Director

Who owns Valeant Pharmaceuticals International stock?

Valeant Pharmaceuticals International's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (1.82%), Acadian Asset Management LLC (0.22%), Academy Capital Management Inc. TX (0.18%), Hexavest Inc. (0.11%), TB Alternative Assets Ltd. (0.07%) and Aperio Group LLC (0.04%). Company insiders that own Valeant Pharmaceuticals International stock include Argeris N Karabelas, Joseph C Papa, Paul Herendeen, Pershing Square Capital Manage, Robert L Rosiello, Ronald Harold Farmer, Schutter Richard U De, Thomas W Sr Ross and Valueact Capital Master Fund,. View Institutional Ownership Trends for Valeant Pharmaceuticals International.

Who sold Valeant Pharmaceuticals International stock? Who is selling Valeant Pharmaceuticals International stock?

Valeant Pharmaceuticals International's stock was sold by a variety of institutional investors in the last quarter, including ING Groep NV, APG Asset Management N.V., Academy Capital Management Inc. TX, Capstone Asset Management Co. and Hexavest Inc.. View Insider Buying and Selling for Valeant Pharmaceuticals International.

Who bought Valeant Pharmaceuticals International stock? Who is buying Valeant Pharmaceuticals International stock?

Valeant Pharmaceuticals International's stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Bank of Montreal Can, TB Alternative Assets Ltd., Aperio Group LLC, Mn Services Vermogensbeheer B.V., Wellington Shields Capital Management LLC, Opera Trading Capital and US Bancorp DE. Company insiders that have bought Valeant Pharmaceuticals International stock in the last two years include Argeris N Karabelas, Joseph C Papa, Paul Herendeen, Robert L Rosiello, Ronald Harold Farmer, Schutter Richard U De, Thomas W Sr Ross and Valueact Capital Master Fund,. View Insider Buying and Selling for Valeant Pharmaceuticals International.

How do I buy Valeant Pharmaceuticals International stock?

Shares of Valeant Pharmaceuticals International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Valeant Pharmaceuticals International's stock price today?

One share of Valeant Pharmaceuticals International stock can currently be purchased for approximately $17.71.


MarketBeat Community Rating for Valeant Pharmaceuticals International (NYSE VRX)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  956 (Vote Outperform)
Underperform Votes:  872 (Vote Underperform)
Total Votes:  1,828
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Valeant Pharmaceuticals International (NYSE:VRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 12 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.05)
Consensus Price Target: $16.89 (4.60% downside)

Analysts' Ratings History for Valeant Pharmaceuticals International (NYSE:VRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017J P Morgan Chase & CoSet Price TargetHold$10.00LowView Rating Details
7/17/2017Deutsche Bank AGSet Price TargetHold$18.00 -> $19.00HighView Rating Details
7/17/2017Stifel NicolausReiterated RatingBuy$35.00LowView Rating Details
7/14/2017Jefferies Group LLCReiterated RatingBuy$18.00LowView Rating Details
7/14/2017Wells Fargo & CompanyReiterated RatingSellLowView Rating Details
7/14/2017Piper Jaffray CompaniesReiterated RatingUnderweight$10.00HighView Rating Details
7/12/2017TD SecuritiesBoost Price TargetHold$15.00 -> $20.00LowView Rating Details
6/28/2017Cantor FitzgeraldBoost Price TargetPositive$18.00 -> $23.00HighView Rating Details
6/20/2017MizuhoReiterated RatingUnderperform$8.00MediumView Rating Details
6/19/2017Royal Bank Of CanadaSet Price TargetSector Perform$19.00MediumView Rating Details
6/17/2017GuggenheimInitiated CoverageBuy$18.00HighView Rating Details
6/9/2017BMO Capital MarketsReiterated RatingMarket Perform$15.00LowView Rating Details
6/8/2017Canaccord GenuitySet Price TargetHold$12.00 -> $14.00HighView Rating Details
5/23/2017Barclays PLCReiterated RatingHold$20.00LowView Rating Details
5/19/2017Rodman & RenshawReiterated RatingNeutral$17.00MediumView Rating Details
5/10/2017HC WainwrightSet Price TargetHold$17.00LowView Rating Details
5/10/2017ScotiabankBoost Price TargetSector Perform$12.00 -> $14.00HighView Rating Details
5/10/2017BTIG ResearchReiterated RatingNeutralMediumView Rating Details
3/11/2017Morgan StanleyReiterated RatingEqual Weight$17.00 -> $12.00N/AView Rating Details
5/29/2016Susquehanna Bancshares IncReiterated RatingHold$105.00N/AView Rating Details
5/29/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
4/1/2016Citigroup Inc.Reiterated RatingBuyN/AView Rating Details
3/22/2016NomuraReiterated RatingNeutral$60.00N/AView Rating Details
3/15/2016CIBCDowngradeSector Perform -> Sector Underperform$90.00 -> $24.00N/AView Rating Details
12/21/2015Bank of America CorporationReiterated RatingBuyN/AView Rating Details
11/23/2015Maxim GroupReiterated RatingHoldN/AView Rating Details
11/2/2015Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$180.00 -> $122.00N/AView Rating Details
10/23/2015Oppenheimer Holdings, Inc.Reiterated RatingMarket PerformN/AView Rating Details
10/19/2015Evercore ISIReiterated RatingBuyN/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Valeant Pharmaceuticals International (NYSE:VRX)
Earnings by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)
Earnings History by Quarter for Valeant Pharmaceuticals International (NYSE VRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/20173/31/2017$0.87$2.80$2.17 billion$2.11 billionViewListenView Earnings Details
2/28/2017Q416$1.20$1.26$2.34 billion$2.40 billionViewListenView Earnings Details
11/8/2016Q316$1.78$1.55$2.49 billion$2.48 billionViewListenView Earnings Details
8/9/2016Q216$1.48$1.40$2.47 billion$2.42 billionViewN/AView Earnings Details
6/7/2016Q116$1.37$1.27$2.34 billion$2.37 billionViewN/AView Earnings Details
3/15/2016Q415$2.61$2.50$2.75 billion$2.80 billionViewListenView Earnings Details
10/19/2015Q315$2.68$2.74$2.06 billion$2.79 billionViewListenView Earnings Details
7/23/2015Q215$2.46$2.58$2.04 million$2.73 millionViewListenView Earnings Details
4/29/2015Q115$2.34$2.36$1.89 billion$2.20 billionViewN/AView Earnings Details
2/24/2015Q414$2.56$2.58$2.23 billion$2.28 billionViewN/AView Earnings Details
10/20/2014Q314$1.99$2.11$2.06 billion$2.06 billionViewListenView Earnings Details
7/31/2014Q214$1.91$1.91$1.06 billion$1.99 billionViewN/AView Earnings Details
5/8/2014Q114$1.72$1.76$1.04 billion$1.85 billionViewN/AView Earnings Details
2/27/2014Q413$2.06$2.15$986.30 million$2.06 billionViewN/AView Earnings Details
10/31/2013Q313$1.40$1.51$884.14 million$1.54 billionViewN/AView Earnings Details
8/7/2013Q213$1.28$1.34$820.09 million$1.10 billionViewN/AView Earnings Details
5/2/2013Q113$1.25$1.30$1.04 billion$1.07 billionViewN/AView Earnings Details
2/28/2013Q412$1.21$1.34$654.17 million$946.67 millionViewN/AView Earnings Details
11/2/2012Q312$1.13$1.15$875.91 million$884.00 millionViewN/AView Earnings Details
8/2/2012$0.99$1.01ViewN/AView Earnings Details
5/3/2012$0.96$0.99ViewN/AView Earnings Details
11/3/2011$0.57$0.66ViewN/AView Earnings Details
8/4/2011$0.65$0.73ViewN/AView Earnings Details
5/9/2011$0.51$0.56ViewN/AView Earnings Details
2/24/2011$0.45$0.51ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Valeant Pharmaceuticals International (NYSE:VRX)
2017 EPS Consensus Estimate: $3.87
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.94$0.94$0.94
Q2 20171$1.01$1.01$1.01
Q3 20171$0.94$0.94$0.94
Q4 20171$0.98$0.98$0.98
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Valeant Pharmaceuticals International (NYSE:VRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Valeant Pharmaceuticals International (NYSE:VRX)
Insider Ownership Percentage: 5.87%
Institutional Ownership Percentage: 50.42%
Insider Trades by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)
Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)
Insider Trades by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/11/2017Schutter Richard U DeDirectorBuy20,000$13.90$278,000.00View SEC Filing  
3/15/2017Schutter Richard U DeDirectorBuy10,000$10.80$108,000.00View SEC Filing  
3/14/2017Paul HerendeenCFOBuy24,000$10.72$257,280.00View SEC Filing  
3/14/2017Valueact Capital Master Fund,InsiderBuy3,000,000$10.82$32,460,000.00View SEC Filing  
3/13/2017Pershing Square Capital ManageDirectorSell18,114,432$11.00$199,258,752.00View SEC Filing  
12/14/2016Thomas W Sr. RossDirectorBuy5,000$14.73$73,650.00View SEC Filing  
12/12/2016Pershing Square Capital ManageDirectorSell3,476,690$14.85$51,628,846.50View SEC Filing  
8/11/2016Argeris N KarabelasDirectorBuy4,000$24.65$98,600.00View SEC Filing  
6/10/2016Joseph C PapaCEOBuy202,000$24.48$4,944,960.00View SEC Filing  
10/21/2015Ronald Harold FarmerDirectorBuy1,500$181.60$272,400.00View SEC Filing  
7/31/2015Robert L RosielloCFOBuy7,875$254.28$2,002,455.00View SEC Filing  
6/12/2015Robert L RosielloEVPBuy12,900$232.51$2,999,379.00View SEC Filing  
6/9/2015Ronald Harold FarmerDirectorBuy1,000$260.63$260,630.00View SEC Filing  
6/8/2015Ronald Harold FarmerDirectorBuy500$289.20$144,600.00View SEC Filing  
6/2/2015Pavel MirovskyEVPSell38,000$238.01$9,044,380.00View SEC Filing  
5/26/2015Anne Clem WhitakerDirectorBuy7,500$234.67$1,760,025.00View SEC Filing  
5/4/2015Robert Roswell Chai-OnnEVPSell90,938$222.54$20,237,342.52View SEC Filing  
12/10/2014Jeffrey W UbbenInsiderBuy250,000$140.06$35,015,000.00View SEC Filing  
12/3/2014Katharine Berghuis StevensonDirectorBuy1,500$145.73$218,595.00View SEC Filing  
11/24/2014Jeffrey W UbbenInsiderBuy210,000$142.25$29,872,500.00View SEC Filing  
6/23/2014Robert Roswell Chai-OnnEVPSell10,203$121.70$1,241,705.10View SEC Filing  
5/13/2014Robert Roswell Chai-OnnEVPSell10,000$130.08$1,300,800.00View SEC Filing  
4/1/2014Norma Ann ProvencioDirectorSell5,000$132.18$660,900.00View SEC Filing  
3/21/2014Laizer KornwasserEVPBuy2,481$134.97$334,860.57View SEC Filing  
2/3/2014Norma Ann ProvencioDirectorSell5,000$136.23$681,150.00View SEC Filing  
1/24/2014Laizer KornwasserEVPBuy2,536$132.15$335,132.40View SEC Filing  
1/13/2014Norma Ann ProvencioDirectorSell5,000$133.00$665,000.00View SEC Filing  
12/14/2013J. Michael PearsonCEOBuy184,247$81.41$14,999,548.27View SEC Filing  
11/18/2013Laizer KornwasserEVPBuy3,500$107.38$375,830.00View SEC Filing  
11/6/2013Ronald Harold FarmerDirectorBuy1,500$107.98$161,970.00View SEC Filing  
9/13/2013Laizer KornwasserEVPBuy1,000$99.02$99,020.00View SEC Filing  
9/6/2013Norma Ann ProvencioDirectorSell4,000$100.25$401,000.00View SEC Filing  
9/3/2013Norma Ann ProvencioDirectorSell5,000$99.68$498,400.00View SEC Filing  
8/29/2013Fred HassanDirectorBuy51,000$99.01$5,049,510.00View SEC Filing  
8/28/2013Ronald Harold FarmerDirectorBuy2,500$102.36$255,900.00View SEC Filing  
8/23/2013Robert Roswell Chai-OnnEVPBuy5,032$99.30$499,677.60View SEC Filing  
8/12/2013Brian StolzEVPBuy4,500$100.71$453,195.00View SEC Filing  
8/9/2013Laizer KornwasserEVPBuy3,500$100.36$351,260.00View SEC Filing  
6/19/2013G Mason MorfitInsiderBuy1,352,941$85.00$114,999,985.00View SEC Filing  
6/12/2013Lloyd Mitchell SegalDirectorBuy3,190$84.16$268,470.40View SEC Filing  
6/11/2013Norma Ann ProvencioDirectorSell6,000$85.26$511,560.00View SEC Filing  
3/11/2013Laizer KornwasserEVPBuy2,000$70.61$141,220.00View SEC Filing  
11/7/2012Brian M StolzEVPBuy2,040$52.76$107,630.40View SEC Filing  
11/6/2012Howard Bradley SchillerCFOBuy18,300$54.10$990,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Valeant Pharmaceuticals International (NYSE:VRX)
Latest Headlines for Valeant Pharmaceuticals International (NYSE:VRX)
Source:
DateHeadline
americanbankingnews.com logoValeant Pharmaceuticals International, Inc. (NYSE:VRX) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 24 at 11:58 AM
fool.com logoValeant Pharmaceuticals and Gilead Sciences both look dirt cheap, but only one of these stocks is a real bargain. - Motley Fool
www.fool.com - July 23 at 9:34 AM
finance.yahoo.com logoSequoia Fund Seen Bouncing Back After Valeant Saga
finance.yahoo.com - July 22 at 10:25 AM
finance.yahoo.com logoThe Unreformed Stock Picker: Without A Boss Bill Miller Is Betting On Amazon, Bitcoin And Bob Dylan
finance.yahoo.com - July 19 at 9:19 AM
finance.yahoo.com logoStreet Talk: Tesla Inc (TSLA), Apple Inc. (AAPL), Valeant Pharmaceuticals Intl Inc (VRX)
finance.yahoo.com - July 19 at 9:19 AM
finance.yahoo.com logoFeatured Company News - Valeant Pharma Divests its Skin Care Business, Obagi Medical Products Business
finance.yahoo.com - July 19 at 9:18 AM
americanbankingnews.com logoValeant Pharmaceuticals International, Inc. (VRX) PT Set at $10.00 by J P Morgan Chase & Co
www.americanbankingnews.com - July 18 at 3:40 PM
americanbankingnews.com logoValeant Pharmaceuticals International, Inc. (VRX) Sees Large Decrease in Short Interest
www.americanbankingnews.com - July 18 at 7:41 AM
americanbankingnews.com logoDeutsche Bank AG Boosts Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Price Target to $19.00
www.americanbankingnews.com - July 17 at 5:58 PM
americanbankingnews.com logoValeant Pharmaceuticals International's (NYSE:VRX) "Buy" Rating Reaffirmed at Stifel Nicolaus
www.americanbankingnews.com - July 17 at 4:04 PM
finance.yahoo.com logoBiotech Scoop: Valeant Pharmaceuticals Intl Inc (VRX), Teva Pharmaceutical (TEVA), and Kite Pharma (KITE)
finance.yahoo.com - July 17 at 11:14 AM
finance.yahoo.com logoValeant Agrees To Sell Obagi Medical Products Business
finance.yahoo.com - July 17 at 11:14 AM
finance.yahoo.com logoValeant agrees to sell Obagi Medical Products for $190 million in cash
finance.yahoo.com - July 17 at 11:14 AM
finance.yahoo.com logoM&A Monday: Church & Dwight, Dominion Diamond, Valeant & More
finance.yahoo.com - July 17 at 11:13 AM
finance.yahoo.com logoStocks to Watch: Procter & Gamble, Blue Apron, Netflix, Citigroup, BlackRock
finance.yahoo.com - July 17 at 11:13 AM
americanbankingnews.com logoValeant Pharmaceuticals International, Inc. (VRX) Earns Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - July 15 at 2:56 PM
seekingalpha.com logoWells bearish on Valeant, sees 49% downside risk - Seeking Alpha
seekingalpha.com - July 14 at 10:09 PM
marketwatch.com logoValeant redeems $500 million of debt, on track to meet or exceed $5 billion debt reduction goal - MarketWatch
www.marketwatch.com - July 14 at 10:09 PM
seekingalpha.com logoValeant: Much More Upside Remains (Part II) - Seeking Alpha
seekingalpha.com - July 14 at 10:09 PM
marketwatch.com logoValeant Announces Redemption Of Remaining Approximately $500 Million Aggregate Principal Amount Of Its ... - MarketWatch
www.marketwatch.com - July 14 at 10:09 PM
americanbankingnews.com logoWells Fargo & Company Reiterates "Underperform" Rating for Valeant Pharmaceuticals International, Inc. (VRX)
www.americanbankingnews.com - July 14 at 7:58 PM
finance.yahoo.com logoValeant Pharmaceuticals’ Overall Trajectory Remains on Edge, Teva Pharmaceutical May Face Difficulty Beating Consensus
finance.yahoo.com - July 14 at 5:04 PM
finance.yahoo.com logoValeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment
finance.yahoo.com - July 14 at 5:04 PM
americanbankingnews.com logoValeant Pharmaceuticals International's (VRX) "Underweight" Rating Reiterated at Piper Jaffray Companies
www.americanbankingnews.com - July 14 at 10:44 AM
finance.yahoo.com logoValeant Announces Redemption Of Remaining Approximately $500 Million Aggregate Principal Amount Of Its Outstanding 6.75% Senior Notes Due 2018
finance.yahoo.com - July 14 at 9:49 AM
finance.yahoo.com logoValeant redeems $500 million of debt, on track to meet or exceed $5 billion debt reduction goal
finance.yahoo.com - July 14 at 9:49 AM
americanbankingnews.com logoZacks Investment Research Lowers Valeant Pharmaceuticals International, Inc. (VRX) to Strong Sell
www.americanbankingnews.com - July 13 at 4:10 PM
finance.yahoo.com logoValeant Continues Quest to Repay Massive $30 Billion Debt Load, Shares Close Higher
finance.yahoo.com - July 12 at 8:24 PM
seekingalpha.com logoValeant: Much More Upside Remains - Seeking Alpha
seekingalpha.com - July 12 at 3:21 PM
finance.yahoo.com logoValeant's Valuation 'Does Not Make Sense,' Warns Piper Jaffray
finance.yahoo.com - July 12 at 3:21 PM
americanbankingnews.com logoTD Securities Increases Valeant Pharmaceuticals International, Inc. (VRX) Price Target to $20.00
www.americanbankingnews.com - July 12 at 2:25 PM
americanbankingnews.com logo Analysts Anticipate Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Will Announce Quarterly Sales of $2.24 Billion
www.americanbankingnews.com - July 12 at 9:34 AM
finance.yahoo.com logoFeatured Company News - Valeant Pharma Pays Off $811 Million in Terms Loans
finance.yahoo.com - July 12 at 9:04 AM
streetinsider.com logoValeant Pharma (VRX) Pays Down $811M of Senior Secured Term Loans - StreetInsider.com
www.streetinsider.com - July 11 at 9:23 AM
americanbankingnews.com logo$0.96 EPS Expected for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) This Quarter
www.americanbankingnews.com - July 10 at 8:08 PM
americanbankingnews.com logoStock Traders Buy High Volume of Put Options on Valeant Pharmaceuticals International (VRX)
www.americanbankingnews.com - July 9 at 7:08 AM
finance.yahoo.com logoBausch + Lomb Japan Launches Bausch + Lomb AQUALOX® Contact Lenses
finance.yahoo.com - July 6 at 5:01 PM
finance.yahoo.com logoJohn Paulson Is Truly a Glutton for Punishment
finance.yahoo.com - July 6 at 5:01 PM
finance.yahoo.com logoValeant: A Long Road Ahead?
finance.yahoo.com - July 6 at 5:01 PM
finance.yahoo.com logoDo Valeant Fundamentals Justify The Decrease In Bearish Sentiment?
finance.yahoo.com - July 6 at 5:01 PM
americanbankingnews.com logoValeant Pharmaceuticals International's (VRX) "Neutral" Rating Reaffirmed at J P Morgan Chase & Co
www.americanbankingnews.com - July 6 at 2:34 PM
americanbankingnews.com logoWells Fargo & Company Reaffirms Underperform Rating for Valeant Pharmaceuticals International, Inc. (VRX)
www.americanbankingnews.com - July 3 at 8:20 PM
americanbankingnews.com logoValeant Pharmaceuticals International, Inc. to Post FY2017 Earnings of $3.56 Per Share, Cantor Fitzgerald Forecasts (VRX)
www.americanbankingnews.com - July 3 at 7:59 AM
finance.yahoo.com logo[$$] Valeant After Ackman: Paulson Logs 26% Gain
finance.yahoo.com - July 2 at 8:26 AM
americanbankingnews.com logoValeant Pharmaceuticals International, Inc. (VRX) Earns Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - June 30 at 12:25 PM
finance.yahoo.com logoSanpower's SVP Says Dendreon Deal Is a Milestone
finance.yahoo.com - June 30 at 1:20 AM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Rite Aid, Conagra, Forestar, Hertz, Bank stocks - Nasdaq
www.nasdaq.com - June 29 at 3:17 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Rite Aid, Constellation, Forestar, Bank stocks - Nasdaq
www.nasdaq.com - June 29 at 3:17 PM
finance.yahoo.com logoValeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA
finance.yahoo.com - June 29 at 3:17 PM
finance.yahoo.com logo5 Reasons Valeant Can Keep Flying
finance.yahoo.com - June 29 at 3:17 PM

Social

Chart

Valeant Pharmaceuticals International (VRX) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff